PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Prostaglandin D2 (PGD2), an arachidonic acid metabolite, is linked to allergic responses, parasitic infections, and tumor development.
• The specific roles and mechanisms of PGD2 in diffuse large B-cell lymphoma (DLBCL) remain unclear.

Purpose of the Study:

• To investigate the role of PGD2 and its receptor CRTH2 in DLBCL.
• To explore the potential of PGD2 as a prognostic biomarker and therapeutic target in DLBCL.

Main Methods:

• Serum PGD2 levels and CRTH2 expression were analyzed in DLBCL patients.
• The effects of varying PGD2 concentrations on DLBCL cell progression, proliferation, apoptosis, cell cycle, and invasion were assessed.
• The impact of high-concentration PGD2 on ROS-mediated DNA damage and drug cytotoxicity was evaluated.
• The interaction between HDAC inhibitors, CRTH2 inhibitors, and PGD2 in DLBCL was examined.

Main Results:

• DLBCL patients exhibited high serum PGD2 concentrations and low CRTH2 expression, correlating with clinical features and prognosis.
• Low-concentration PGD2 promoted DLBCL cell growth, while high-concentration PGD2 inhibited it by affecting proliferation, apoptosis, cell cycle, and invasion.
• High-concentration PGD2 induced ROS-mediated DNA damage and enhanced the efficacy of adriamycin, bendamustine, and venetoclax.
• HDAC inhibitors and a CRTH2 inhibitor modulated CRTH2 expression and PGD2 production, with synergistic anti-tumor effects observed with high-concentration PGD2.

Conclusions:

• PGD2 and CRTH2 are identified as novel prognostic biomarkers in DLBCL.
• High-concentration PGD2 demonstrates potential as a therapeutic strategy for DLBCL, enhancing drug cytotoxicity and anti-tumor effects.
• Targeting PGD2 and CRTH2 pathways offers promising therapeutic avenues for DLBCL treatment.